Evaluation of Dental Implants As a Risk Factor for the Development of Bisphosphonate-related Osteonecrosis of the Jaw in Breast Cancer Patients

Overview

Journal Odontology

Specialty Dentistry

Date 2015 May 10

PMID 25956267

Citations 11

Authors

Akira Matsuo

Hayato Hamada

Hidetoshi Takahashi

Ayako Okamoto

Hiroshi Kaise

Daichi Chikazu

Affiliations

Soon will be listed here.

Abstract

It remains unclear whether dental implants are a risk factor for the development of bisphosphonate-related osteonecrosis of the jaw (BRONJ). We retrospectively evaluated the status of dental implants in patients given intravenous bisphosphonates (BPs) in a breast cancer cohort to elucidate the risk for BRONJ at the implant site. We established a BRONJ oral monitoring program for 247 breast cancer patients given intravenous BP in our institution. The 3-year cumulative incidence rate was determined. The systemic and local risk factors of 44 patients who completed comprehensive oral examinations were evaluated by logistic regression analysis. The 3-year cumulative incidence rate of the 247 patients was 0.074 % (8/247, 95 % CI 0.0081-0.014). In the 44 orally examined patients, 6 (13.6 %: 6/44) had dental implants. Of these 6 patients, 1 developed BRONJ at the implant site. There were no significant differences in the age, total BP treatment period, number of residual teeth, time of regular oral monitoring, oral hygiene level, or dental implant insertion. Although a case of ONJ was identified, dental implants which were inserted before intravenous BP administration were not a risk factor for the development of ONJ in breast cancer patients.

Citing Articles

Peri-implantitis increases the risk of medication-related osteonecrosis of the jaws associated with osseointegrated implants in rats treated with zoledronate.

Quintao Manhanini Souza E, Toro L, Ganzaroli V, de Oliveira Alvarenga Freire J, Matsumoto M, Casatti C Sci Rep. 2024; 14(1):627.

PMID: 38182598 PMC: 10770413. DOI: 10.1038/s41598-023-49647-4.

Antiresorptive therapy and dental implant survival: an up to 20-year retrospective cohort study in women.

Cheng Y, Ewers R, Morgan K, Hirayama M, Murcko L, Morgan J Clin Oral Investig. 2022; 26(11):6569-6582.

PMID: 36001145 DOI: 10.1007/s00784-022-04609-4.

Review and Update of the Risk Factors and Prevention of Antiresorptive-Related Osteonecrosis of the Jaw.

Kim H Endocrinol Metab (Seoul). 2021; 36(5):917-927.

PMID: 34674506 PMC: 8566140. DOI: 10.3803/EnM.2021.1170.

Prevalence and risk factors of medication-related osteonecrosis of the jaw in osteoporotic and breast cancer patients: a cross-sectional study.

Soares A, Simon S, Gebrim L, Nazario A, Lazaretti-Castro M Support Care Cancer. 2019; 28(5):2265-2271.

PMID: 31468192 DOI: 10.1007/s00520-019-05044-0.

Novel insight into the management of bisphosphonate-related osteonecrosis of the jaw (BRONJ).

Kishimoto H, Noguchi K, Takaoka K Jpn Dent Sci Rev. 2019; 55(1):95-102.

PMID: 31193410 PMC: 6526304. DOI: 10.1016/j.jdsr.2018.09.002.

References

Ripamonti C, Maniezzo M, Campa T, Fagnoni E, Brunelli C, Saibene G . Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol. 2008; 20(1):137-45. DOI: 10.1093/annonc/mdn526. View

Reginster J, Neuprez A, Beaudart C, Lecart M, Sarlet N, Bernard D . Antiresorptive drugs beyond bisphosphonates and selective oestrogen receptor modulators for the management of postmenopausal osteoporosis. Drugs Aging. 2014; 31(6):413-24. PMC: 4033814. DOI: 10.1007/s40266-014-0179-z. View

Coleman R . Skeletal complications of malignancy. Cancer. 1997; 80(8 Suppl):1588-94. DOI: 10.1002/(sici)1097-0142(19971015)80:8+<1588::aid-cncr9>3.3.co;2-z. View

Chadha G, Ahmadieh A, Kumar S, Sedghizadeh P . Osseointegration of dental implants and osteonecrosis of the jaw in patients treated with bisphosphonate therapy: a systematic review. J Oral Implantol. 2013; 39(4):510-20. DOI: 10.1563/AAID-JOI-D-11-00234. View

Fugazzotto P, Lightfoot W, Jaffin R, Kumar A . Implant placement with or without simultaneous tooth extraction in patients taking oral bisphosphonates: postoperative healing, early follow-up, and the incidence of complications in two private practices. J Periodontol. 2007; 78(9):1664-9. DOI: 10.1902/jop.2007.060514. View

Kwon T, Lee C, Park J, Choi S, Rijal G, Shin H . Osteonecrosis associated with dental implants in patients undergoing bisphosphonate treatment. Clin Oral Implants Res. 2013; 25(5):632-40. DOI: 10.1111/clr.12088. View

Khosla S, Burr D, Cauley J, Dempster D, Ebeling P, Felsenberg D . Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007; 22(10):1479-91. DOI: 10.1359/jbmr.0707onj. View

Bedogni A, Saia G, Bettini G, Tronchet A, Totola A, Bedogni G . Long-term outcomes of surgical resection of the jaws in cancer patients with bisphosphonate-related osteonecrosis. Oral Oncol. 2011; 47(5):420-4. DOI: 10.1016/j.oraloncology.2011.02.024. View

Salvi G, Zitzmann N . The effects of anti-infective preventive measures on the occurrence of biologic implant complications and implant loss: a systematic review. Int J Oral Maxillofac Implants. 2014; 29 Suppl:292-307. DOI: 10.11607/jomi.2014suppl.g5.1. View

10.

Williamson R . Surgical management of bisphosphonate induced osteonecrosis of the jaws. Int J Oral Maxillofac Surg. 2009; 39(3):251-5. DOI: 10.1016/j.ijom.2009.11.014. View

11.

Hess L, Jeter J, Benham-Hutchins M, Alberts D . Factors associated with osteonecrosis of the jaw among bisphosphonate users. Am J Med. 2008; 121(6):475-483.e3. PMC: 2601671. DOI: 10.1016/j.amjmed.2008.01.047. View

12.

Dimopoulos M, Kastritis E, Bamia C, Melakopoulos I, Gika D, Roussou M . Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol. 2008; 20(1):117-20. DOI: 10.1093/annonc/mdn554. View

13.

Eidtmann H, de Boer R, Bundred N, Llombart-Cussac A, Davidson N, Neven P . Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol. 2010; 21(11):2188-2194. DOI: 10.1093/annonc/mdq217. View

14.

Vescovi P, Campisi G, Fusco V, Mergoni G, Manfredi M, Merigo E . Surgery-triggered and non surgery-triggered Bisphosphonate-related Osteonecrosis of the Jaws (BRONJ): A retrospective analysis of 567 cases in an Italian multicenter study. Oral Oncol. 2011; 47(3):191-4. DOI: 10.1016/j.oraloncology.2010.11.007. View

15.

Ruggiero S, Dodson T, Fantasia J, Goodday R, Aghaloo T, Mehrotra B . American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg. 2014; 72(10):1938-56. DOI: 10.1016/j.joms.2014.04.031. View

16.

Jacobsen C, Metzler P, Rossle M, Obwegeser J, Zemann W, Gratz K . Osteopathology induced by bisphosphonates and dental implants: clinical observations. Clin Oral Investig. 2012; 17(1):167-75. DOI: 10.1007/s00784-012-0708-2. View

17.

Van den Wyngaert T, Claeys T, Huizing M, Vermorken J, Fossion E . Initial experience with conservative treatment in cancer patients with osteonecrosis of the jaw (ONJ) and predictors of outcome. Ann Oncol. 2008; 20(2):331-6. DOI: 10.1093/annonc/mdn630. View

18.

Khan A, Sandor G, Dore E, Morrison A, Alsahli M, Amin F . Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol. 2008; 35(7):1391-7. View

19.

Mattheos N, Caldwell P, Petcu E, Ivanovski S, Reher P . Dental implant placement with bone augmentation in a patient who received intravenous bisphosphonate treatment for osteoporosis. J Can Dent Assoc. 2013; 79:d2. View

20.

Kyrgidis A, Tzellos T, Toulis K, Arora A, Kouvelas D, Triaridis S . An evidence-based review of risk-reductive strategies for osteonecrosis of the jaws among cancer patients. Curr Clin Pharmacol. 2012; 8(2):124-34. DOI: 10.2174/1574884711308020005. View